肾移植受者中每月一次聚乙二醇化促红细胞生成素β与每两周一次达贝泊汀α的对比：一项随机试验。 - Suppr

Once-monthly pegylated epoetin Beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial.

作者信息

Campistol Josep M, Carreño Agustín, Morales José M, Pallardó Luis, Franco Antonio, Navarro Dolores, Grinyó Josep M, Montenegro Jesús, Sánchez Fructuoso Ana I, Romero Ramón, Guirado Luis, Arias Manuel

出版信息

Transplantation. 2013 Jan 27;95(2):e6-e10. doi: 10.1097/TP.0b013e3182782f3a.

DOI:10.1097/TP.0b013e3182782f3a

PMID:23325012

Abstract

摘要

相似文献

Once-monthly pegylated epoetin Beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial.肾移植受者中每月一次聚乙二醇化促红细胞生成素β与每两周一次达贝泊汀α的对比：一项随机试验。

Transplantation. 2013 Jan 27;95(2):e6-e10. doi: 10.1097/TP.0b013e3182782f3a.

Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.C.E.R.A. 在儿科血液透析伴慢性肾脏病贫血患者中的维持治疗的疗效和长期安全性。

Clin J Am Soc Nephrol. 2018 Jan 6;13(1):81-90. doi: 10.2215/CJN.03570417. Epub 2017 Nov 2.

Efficacy and safety of once-monthly continuous erythropoietin receptor activator in patients with chronic renal anemia.每月一次持续使用促红细胞生成素受体激活剂治疗慢性肾性贫血患者的疗效和安全性。

J Nephrol. 2013 Nov-Dec;26(6):1114-21. doi: 10.5301/jn.5000251. Epub 2013 Sep 13.

Comparison of pain and efficacy of darbepoetin alfa and epoetin Beta pegol treatment in patients receiving peritoneal dialysis.接受腹膜透析患者中，达贝泊汀α与聚乙二醇化促红细胞生成素β治疗的疼痛及疗效比较。

J Nippon Med Sch. 2015;82(1):21-6. doi: 10.1272/jnms.82.21.

C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study.对于未接受透析的慢性肾病患者，每4周一次使用C.E.R.A.：ARCTOS扩展研究。

Hemodial Int. 2010 Apr;14(2):233-9. doi: 10.1111/j.1542-4758.2009.00421.x. Epub 2009 Nov 3.

C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis.C.E.R.A. 可维持拉美透析患者的血红蛋白稳定。

Int Urol Nephrol. 2013 Oct;45(5):1355-64. doi: 10.1007/s11255-012-0272-3. Epub 2012 Sep 19.

Efficacy of a simple dosage scheme to convert from shorter-acting erythropoiesis-stimulating agent to continuous erythropoietin receptor activator in kidney transplantation patients.一种简单给药方案在肾移植患者中从短效促红细胞生成素刺激剂转换为持续促红细胞生成素受体激活剂的疗效。

Transplant Proc. 2015 Jan-Feb;47(1):73-5. doi: 10.1016/j.transproceed.2014.12.006.

Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.未接受透析的慢性肾脏病患者对每月一次注射用重组人促红细胞生成素α给药的偏好。

Curr Med Res Opin. 2006 Oct;22(10):2023-30. doi: 10.1185/030079906X148283.

Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis.聚乙二醇化促红细胞生成素α每月一次可纠正未接受透析的慢性肾病患者的贫血。

Nephrology (Carlton). 2014 May;19(5):266-74. doi: 10.1111/nep.12214.

Renal prognoses by different target hemoglobin levels achieved by epoetin beta pegol dosing to chronic kidney disease patients with hyporesponsive anemia to erythropoiesis-stimulating agent: a multicenter open-label randomized controlled study.聚乙二醇化重组人促红素-β治疗对红细胞生成刺激剂反应低下的慢性肾脏病贫血患者的不同目标血红蛋白水平与肾脏预后的相关性：一项多中心、开放标签、随机对照研究。

Clin Exp Nephrol. 2021 May;25(5):456-466. doi: 10.1007/s10157-020-02005-4. Epub 2021 Jan 7.

引用本文的文献

Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.促红细胞生成素刺激剂治疗慢性肾脏病成人贫血的网状 Meta 分析。

Cochrane Database Syst Rev. 2023 Feb 13;2(2):CD010590. doi: 10.1002/14651858.CD010590.pub3.

Monthly Continuous Erythropoietin Receptor Activator Versus Weekly Epoetin-Beta, Similar Hemoglobinization but Different Anisocytosis Degree in Hemodialysis Patients: A Randomized Controlled Trial.血液透析患者中每月一次持续促红细胞生成素受体激活剂与每周一次促红细胞生成素-β的比较：血红蛋白化相似但红细胞大小不均一程度不同的随机对照试验

J Hematol. 2021 Dec;10(6):255-265. doi: 10.14740/jh862. Epub 2021 Nov 29.

Treatment of anemia in difficult-to-manage patients with chronic kidney disease.慢性肾脏病难治性患者贫血的治疗

Kidney Int Suppl (2011). 2021 Apr;11(1):26-34. doi: 10.1016/j.kisu.2020.12.006. Epub 2021 Mar 18.

Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease.用于治疗慢性肾脏病贫血的持续促红细胞生成素受体激活剂（CERA）

Cochrane Database Syst Rev. 2017 Aug 7;8(8):CD009904. doi: 10.1002/14651858.CD009904.pub2.

Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and meta-analysis.比较 ESA 生物类似药与原研药在慢性肾脏病成人患者中的疗效和安全性：系统评价和荟萃分析。

J Nephrol. 2018 Jun;31(3):321-332. doi: 10.1007/s40620-017-0419-5. Epub 2017 Jun 23.

Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.促红细胞生成素用于治疗成人慢性肾脏病贫血：一项网状Meta分析

Cochrane Database Syst Rev. 2014 Dec 8;2014(12):CD010590. doi: 10.1002/14651858.CD010590.pub2.

Darbepoetin for the anaemia of chronic kidney disease.达贝泊汀用于治疗慢性肾脏病贫血

Cochrane Database Syst Rev. 2014 Mar 31;2014(3):CD009297. doi: 10.1002/14651858.CD009297.pub2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Once-monthly pegylated epoetin Beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献